ホーム › 悪性黒色腫 › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける悪性黒色腫の臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、悪性黒色腫に関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
被験者募集中第3相
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
被験者募集中第3相
- Allegheny Health Network, Pittsburgh
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
被験者募集中第2相
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
被験者募集中第3相
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
被験者募集中第2相
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site, Pittsburgh
Investigating Real-Time Immunotherapy Symptoms Study
被験者募集中
- UPMC Hillman Cancer Center, Pittsburgh
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
被験者募集中第1/2相
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
被験者募集中第2相
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
被験者募集中観察研究
- UPMC Hillman Cancer Center, Pittsburgh
Evaluation of Hypoxia in Primary Melanoma
被験者募集中観察研究
- UPMC Hillman Cancer Center, Pittsburgh
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Neoadjuvant Darovasertib in Primary Uveal Melanoma
被験者募集中第3相
- UPMC Hillman Cancer Center, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
被験者募集中第1/2相
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
被験者募集中第2相
- UPMC Hillman Cancer Center, Pittsburgh
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
被験者募集中早期第1相
- UPMC Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
被験者募集中第1相
- UPMC- Hillman Cancer Center, Pittsburgh
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- UPMC Hillman Cancer Center, Pittsburgh
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
被験者募集中第3相
- UPMC Hillman Cancer Center, Pittsburgh
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
被験者募集中観察研究
- UPMC Hillman Cancer Center, Pittsburgh
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
被験者募集中第1/2相
- University of Pittsburgh, Pittsburgh
他の都市における悪性黒色腫の試験
- Houston, TX59件の研究
- New York City, NY38件の研究
- Los Angeles, CA34件の研究
- Nashville, TN33件の研究
- Boston, MA26件の研究
- Philadelphia, PA23件の研究
- San Francisco, CA22件の研究
- Durham, NC21件の研究
- Atlanta, GA21件の研究
- St. Louis, MO21件の研究
- Salt Lake City, UT21件の研究
- Columbus, OH21件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 大腸癌32件の研究
- 転移性癌31件の研究
- 卵巣がん30件の研究
- 子宮内膜がん23件の研究
- 肺がん23件の研究
- 前立腺がん23件の研究
- 脳卒中22件の研究
- 頭頸部扁平上皮癌22件の研究
- うつ病22件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。